Benjamin A Steinberg1, Anne S Hellkamp2, Yuliya Lokhnygina2, Jonathan L Halperin3, Günter Breithardt4, Rod Passman5, Graeme J Hankey6, Manesh R Patel2, Richard C Becker7, Daniel E Singer8, Werner Hacke9, Scott D Berkowitz10, Christopher C Nessel11, Kenneth W Mahaffey12, Keith A A Fox13, Robert M Califf14, Jonathan P Piccini2. 1. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. Electronic address: benjamin.steinberg@dm.duke.edu. 2. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 3. Cardiovascular Institute, Mount Sinai Medical Center, New York, New York. 4. Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster, Germany. 5. Northwestern University Feinberg School of Medicine, Chicago, Illinois. 6. School of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia. 7. University of Cincinnati College of Medicine, Cincinnati, Ohio. 8. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 9. Ruprecht-Karls-University, Heidelberg, Germany. 10. Bayer HealthCare Pharmaceuticals, Montville, New Jersey. 11. Janssen Research & Development LLC, Raritan, New Jersey. 12. Department of Medicine, Stanford University, Stanford, California. 13. University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. 14. Duke Translational Medicine Institute, Duke University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Antiarrhythmic drugs (AADs) and anticoagulation are mainstays of atrial fibrillation (AF) treatment. OBJECTIVE: To study the use and outcomes of AAD therapy in anticoagulated patients with AF. METHODS: Patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial (N = 14,264) were stratified by AAD use at baseline: amiodarone, other AAD, or no AAD. Multivariable adjustment was performed to compare stroke, bleeding, and death across AAD groups as well as across treatment assignment (rivaroxaban or warfarin). RESULTS: Of 14,264 patients randomized, 1681 (11.8%) were treated with an AAD (1144 [8%] with amiodarone and 537 [3.8%] with other AADs). Amiodarone-treated patients were less often female (38% vs 48%), had more persistent AF (64% vs 40%), and more concomitant heart failure (71% vs 41%) than were patients receiving other AADs. Patients receiving no AAD more closely resembled amiodarone-treated patients. Time in therapeutic range was significantly lower in warfarin-treated patients receiving amiodarone than in those receiving no AAD (50% vs 58%; P < .0001). Compared with no AAD, neither amiodarone (adjusted hazard ratio [HR] 0.98; 95% confidence interval [CI] 0.74-1.31; P = .9) nor other AADs (adjusted HR 0.66; 95% CI 0.37-1.17; P = .15) were associated with increased mortality. Similar results were observed for embolic and bleeding outcomes. Treatment effects of rivaroxaban vs warfarin in patients receiving no AAD were consistent with results from the overall trial (primary end point: adjusted HR 0.82; 95% CI 0.68-0.98; Pinteraction = .06; safety end point: adjusted HR 1.12; 95% CI 0.90-1.24; Pinteraction = .33). CONCLUSION: Treatment with AADs was not associated with increased morbidity or mortality in anticoagulated patients with AF. The effect of amiodarone on outcomes in patients receiving rivaroxaban requires further investigation.
RCT Entities:
BACKGROUND: Antiarrhythmic drugs (AADs) and anticoagulation are mainstays of atrial fibrillation (AF) treatment. OBJECTIVE: To study the use and outcomes of AAD therapy in anticoagulated patients with AF. METHODS:Patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial (N = 14,264) were stratified by AAD use at baseline: amiodarone, other AAD, or no AAD. Multivariable adjustment was performed to compare stroke, bleeding, and death across AAD groups as well as across treatment assignment (rivaroxaban or warfarin). RESULTS: Of 14,264 patients randomized, 1681 (11.8%) were treated with an AAD (1144 [8%] with amiodarone and 537 [3.8%] with other AADs). Amiodarone-treated patients were less often female (38% vs 48%), had more persistent AF (64% vs 40%), and more concomitant heart failure (71% vs 41%) than were patients receiving other AADs. Patients receiving no AAD more closely resembled amiodarone-treated patients. Time in therapeutic range was significantly lower in warfarin-treated patients receiving amiodarone than in those receiving no AAD (50% vs 58%; P < .0001). Compared with no AAD, neither amiodarone (adjusted hazard ratio [HR] 0.98; 95% confidence interval [CI] 0.74-1.31; P = .9) nor other AADs (adjusted HR 0.66; 95% CI 0.37-1.17; P = .15) were associated with increased mortality. Similar results were observed for embolic and bleeding outcomes. Treatment effects of rivaroxaban vs warfarin in patients receiving no AAD were consistent with results from the overall trial (primary end point: adjusted HR 0.82; 95% CI 0.68-0.98; Pinteraction = .06; safety end point: adjusted HR 1.12; 95% CI 0.90-1.24; Pinteraction = .33). CONCLUSION: Treatment with AADs was not associated with increased morbidity or mortality in anticoagulated patients with AF. The effect of amiodarone on outcomes in patients receiving rivaroxaban requires further investigation.
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: Emile G Daoud; Taya V Glotzer; D George Wyse; Michael D Ezekowitz; Christopher Hilker; Jodi Koehler; Paul D Ziegler Journal: Heart Rhythm Date: 2011-04-23 Impact factor: 6.343
Authors: Jonathan S Steinberg; Ara Sadaniantz; Jack Kron; Andrew Krahn; D Marty Denny; James Daubert; W Barton Campbell; Edward Havranek; Katherine Murray; Brian Olshansky; Gearoid O'Neill; Magdi Sami; Stanley Schmidt; Randle Storm; Miguel Zabalgoitia; John Miller; Mary Chandler; Elaine M Nasco; H Leon Greene Journal: Circulation Date: 2004-03-29 Impact factor: 29.690
Authors: Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Günter Breithardt Journal: J Am Coll Cardiol Date: 2013-03-14 Impact factor: 24.094
Authors: Yi Wan; Carl Heneghan; Rafael Perera; Nia Roberts; Jennifer Hollowell; Paul Glasziou; Clare Bankhead; Yongyong Xu Journal: Circ Cardiovasc Qual Outcomes Date: 2008-11-05
Authors: Sarah Hanigan; Jessica Das; Kristen Pogue; Geoffrey D Barnes; Michael P Dorsch Journal: J Thromb Thrombolysis Date: 2020-05 Impact factor: 2.300
Authors: David Sanborn; Alan Sugrue; Mustapha Amin; Ramila Mehta; Medhat Farwati; Abhishek J Deshmukh; Haarini Sridhar; Azza Ahmed; Samuel J Asirvatham; Narith N Ou; Peter A Noseworthy; Ammar M Killu; Siva K Mulpuru; Malini Madhavan Journal: Am J Cardiol Date: 2021-10-27 Impact factor: 2.778
Authors: Todd A Miano; Wei Yang; Michael G S Shashaty; Athena Zuppa; Jeremiah R Brown; Sean Hennessy Journal: Clin Pharmacol Ther Date: 2020-03-26 Impact factor: 6.875
Authors: Aditya J Ullal; Claire T Than; Jun Fan; Susan Schmitt; Alexander C Perino; Daniel W Kaiser; Paul A Heidenreich; Susan M Frayne; Ciaran S Phibbs; Mintu P Turakhia Journal: Am Heart J Date: 2015-07-26 Impact factor: 4.749